News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galena Biopharma  (GALE) Initiates RELIEF Patient Registry for Abstral® (fentanyl) Sublingual Tablets


9/3/2013 9:48:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PORTLAND, Ore., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the initiation of the Company's Institutional Review Board (IRB)-approved cancer patient registry study entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of AbstralĀ® (fentanyl) Sublingual Tablets. RELIEF is a post-marketing multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. Abstral is available to patients and health care professionals at pharmacies nationwide, and recruitment and enrollment for the registry trial is underway.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES